CYP26A1: Cytochrome P450 26A1
A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CYP26A1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Talarozole | Phase 2 | GSK | Small molecule | InhibitorCytochrome P450 26A1 inhibitor | 0 |
- Metabolic disease0.43
- Hyperlipidemia0.43
- Alcohol drinking0.41
- Hypercholesterolemia0.41
- Familial lipoprotein lipase deficiency0.38
- Metabolic syndrome0.38
- Abnormality of the skeletal system0.37
- Open-angle glaucoma0.34
- Familial hyperlipidemia0.33
- Refractive error0.33
- Physical activity0.30
- Glaucoma0.29
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5141, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O43174, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets